Back to event calendar

CALAsia 2010

CALAsia is a global conference aimed at helping U.S. and Asian life science organizations spotlight their growth, technology development and innovation in their respective regions. The two day event in San Diego on October 4-5, 2010 will focus on development strategies in the US and Pacific Rim including regulatory compliance issues facing Asian and American companies, the future of global drug discovery, and financing opportunities in Asia.

A host of workshops, plenary presentations for industry leaders, and dozens of company presentations will enable you to showcase your services, products and programs to the partner you have been searching for. You will find these partners among the hundreds of pharmaceutical and biotech executives attending the event, along with industry consultants, CROs and regulatory officials.

In its second year, CALAsia is rapidly becoming the major networking and deal-making opportunity for North American and Asian biopharmaceutical companies. BIOCOM has created and managed successful, highly attended global conferences for nearly 20 years.

Program to include:

The Emerging Markets of China and India
The huge potential of the biopharmaceutical markets in China and India make these markets impossible to ignore for foreign companies. Both markets are poised to grow exponentially in the next 5 - 10 years as their governments invest in expanding their healthcare infrastructure. Indeed, the potential these markets represent have commanded attention of the large pharmaceutical players many of whom have established operations in both markets. And, both countries are focused on investing in and expanding their innovative drug development sectors. What does this mean for the western biotechnology industry? What are the opportunities and challenges? What do biotech executives need to know about both these markets today to position their companies for the future?

Speakers:
•Hank Nordhoff, Chairman, Gen-Probe
•Anula Jayasuriya, President, EPPIC
•Helen Chen, Head of China Life Sciences, L.E.K Consulting

Top US-Asia Deals: The do's and don'ts - Case Studies
Sponsor: Roth Capital Partners
Discussion on the deals beyond why the deal is done but cover what does the collaboration mean moving forward, how will this deal impact. Ensure there is a focus on big and small deals, as well as local deals...

Speakers:
•Mitch Truelock, Managing Director, Investment Banking, ROTH Capital Partners
•Jonathan Mow, VP, Amylin Pharmaceuticals
•Cytori Therapeutics
•Shintaro Asako, CFO, MediciNova

Considerations In Establishing an Operation in Asia
Representatives from life science and medical companies with operations in China and India will discuss their process of evaluation and what factors led them to establishing an operation in China or India. Look at incorporating medical device into this, broaden beyond China and India, cover R&D and sales component.. Also look at considerations that went into setting up operations, experiences, differences within the markets etc.

Speakers:
•Joel Marcus, Alexandria Real Estate
•Gary Titus, SciClone Pharma
•Michael Farrell, ResMed

China's Healthcare Market - What Does Increased Government Spending Mean for Life Science companies
Earlier this year, the Chinese government confirmed their intentions to expand healthcare coverage and improve medical care. The 2009 the government expenditure on healthcare increase 50% over the previous year to $18.75 billion. IMS Health predicts the Chinese market will see a 22% compound annual growth rate in 2010-2013. While it is true that much of this spending is targeted toward building healthcare infrastructure, industry thought leaders think this may be the leading edge of a rise in the purchase of prescription drugs and a move away from traditional medicine.

Speakers:
•Hongbo Lu, Sr. Research Analyst, Piper Jaffray
•Jeff Parker
•Jonathan Zifferblatt, MD, General Biologics

China Session
BAY HELIX SESSION

The Indian Biotechnology Industry: It's Growing
India has a strong and increasingly sophisticated pharmaceutical industry that some think will position India to become a competitor in key therapeutic areas and a partner in others. Indeed, India has considerable CMO expertise; it is a leader in vaccine and generic production; and, many major pharma companies have operations there. India also has an emerging innovative drug development sector supported by a highly educated, English speaking population. This panel will focus on the opportunities for an emerging biotech company to consider.

Speakers:
•Vis Niranjan, President, RxMD
•Bob Easton, Scisive Consulting

Drug Discovery and Asia's Research Institutions
There is no question that Asia has a vast number of excellent academic research institutions that have attracted the attention biopharmaceutical companies for drug discovery. This panel will discuss the hot spots of drug discovery in Asia, the deals that have been done with western pharma and biotech companies and ponder the question of whether Asian institutions could ever replace the NIH.

Speakers:
•Jing-Shan Hu, Ph.D. , Director, Licensing & External Research, Merck & Co.
•Richard Soll, Sr. VP of Integrated Services, WuXi AppTec

*************

Additional CALAsia 2010 Elements:

• Exhibit hall (click here for more information)
• Company presentations (click here for more information)

Highlights from CALAsia 2009:

• Keynote Speakers included: G. Steven Burrill from Burril & Company, George Sarmiento from Astellas Pharmaceuticals Global Development, James Li from Kleiner, Perkins, Caufield and Byers
• Discussions around financing, deal development, regulatory issues, licensing and Innovation
• Countries represented: Japan, Korea, India, Australia, USA, China, South Africa

When

Monday, October 4, 2010 - Tuesday, October 5, 2010

Add to Calendar

RSVP

Friday, October 1, 2010 12:00 p.m.

Where

San Diego Marriott Hotel & Marina 333 West Harbor Drive San Diego, California 92101

Get Driving Directions

Planner

Jennifer Landress